簡(jiǎn)要描述:NDUFB9蛋白抗體免 疫 原;KLH conjugated synthetic peptide derived from human NDUFB9: 1-100/179
產(chǎn)品分類(lèi)
Product Category相關(guān)文章
Related Articles詳細(xì)介紹
NDUFB9蛋白抗體
產(chǎn)品名稱(chēng) | 英文名稱(chēng) | 貨號(hào) |
NDUFB9蛋白抗體 | NDUFB9 | GOY-01K2609 |
商品屬性:
英文名稱(chēng): NDUFB9
中文名:NDUFB9蛋白抗體
別 名;B22; CI B22;
CI-B22; complex I B22 subunit; Complex I-B22; DKFZp566O173; FLJ22885; I B22;
LYR motif containing protein 3; LYR motif-containing protein 3; LYRM3; NADH
dehydrogenase (ubiquinone) 1 beta subcomplex, 9, 22kDa; NADH dehydrogenase
[ubiquinone] 1 beta subcomplex subunit 9; NADH dehydrogenase [ubiquinone] 1
beta subcomplex subunit 9; NADH ubiquinone oxidoreductase B22 subunit;
NADH-ubiquinone oxidoreductase B22 subunit; NDUB9_HUMAN; Ndufb9; UQOR22.
研究領(lǐng)域;腫瘤 細(xì)胞生物 信號(hào)轉(zhuǎn)導(dǎo) 新陳代謝
抗體來(lái)源;Rabbit
克隆類(lèi)型;Polyclonal
交叉反應(yīng);(predicted:
Human, Mouse, Rat, Cow, Horse, )
產(chǎn)品應(yīng)用;WB=1:500-2000
ELISA=1:5000-10000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 (石蠟切片需做抗原修復(fù))
not yet tested in
other applications.
optimal
dilutions/concentrations should be determined by the end user.
理論分子量;22kDa
細(xì)胞定位;細(xì)胞漿
性 狀;Liquid
濃 度;1mg/ml
免 疫 原;KLH
conjugated synthetic peptide derived from human NDUFB9: 1-100/179
亞 型;IgG
純化方法;affinity
purified by Protein A
緩 沖 液;0.01M
TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
注意事項(xiàng);This
product as supplied is intended for research use only, not for use in human,
therapeutic or diagnostic applications.
產(chǎn)品介紹:
NDUFB9 is a 179 amino acid protein that belongs to
the complex I LYR family. Localized to the inner mitochondrial membrane, as
well as to the matrix side of the peripheral membrane, NDUFB9 functions as an
accessory subunit of the multi-subunit mitochondrial membrane respiratory
chain NADH dehydrogenase complex I. Complex I plays an important role in the
transfer of electrons from NADH to the respiratory chain, a process that is
essential for cellular respiration. The gene encoding NDUFB9 maps to human
chromosome 8, which consists of nearly 146 million base pairs, houses more
than 800 genes and is associated with a variety of diseases and malignancies.
Schizophrenia, bipolar disorder, Trisomy 8, Pfeiffer syndrome, congenital
hypothyroidism, Waardenburg syndrome and some leukemias and lymphomas are
thought to occur as a result of defects in specific genes that map to
chromosome 8. Accessory subunit of the mitochondrial membrane
respiratory chain NADH dehydrogenase (Complex I), that is believed to be not
involved in catalysis. Complex I functions in the transfer of electrons from
NADH to the respiratory chain. The immediate electron acceptor for the enzyme
is believed to be ubiquinone. |
多克隆抗體制備:
我公司合成抗原,保證陽(yáng)性血清和抗體ELISA效價(jià)達(dá)到1:32000,由蛋白抗原制備的多抗,保證WB檢測(cè)結(jié)果是陽(yáng)性。技術(shù)服務(wù)實(shí)行分步報(bào)價(jià),按節(jié)點(diǎn)收費(fèi),為客戶(hù)節(jié)約成本。
鼠單克隆抗體制備:
客戶(hù)可根據(jù)項(xiàng)目實(shí)際需求情況靈活選擇進(jìn)行,我公司將為您的項(xiàng)目提供專(zhuān)業(yè)的建議。在制備過(guò)程中,與客戶(hù)互動(dòng)驗(yàn)證,確保最終制備的抗體ELISA陽(yáng)性血清檢測(cè)達(dá)到合同要求的同時(shí),也能滿(mǎn)足客戶(hù)抗體最終應(yīng)用驗(yàn)證需求。技術(shù)服務(wù)實(shí)行分步報(bào)價(jià),按節(jié)點(diǎn)收費(fèi),為客戶(hù)節(jié)約成本。
重組抗體表達(dá)服務(wù):
重組抗體技術(shù)使制備人源化抗體和人源抗體成為可能,而這是其他常規(guī)的多克隆或單克隆抗體制備方法無(wú)法做到的。我公司已搭建好的抗體測(cè)序、重組抗體表達(dá)等先進(jìn)平臺(tái),能為客戶(hù)提供各種類(lèi)型的重組抗體表達(dá)服務(wù),包含鼠源單克隆抗體構(gòu)建及表達(dá)、更換恒定區(qū)亞型的嵌合抗體表達(dá),抗體人源化改造及表達(dá)等服務(wù)。
單項(xiàng)免疫學(xué)及檢測(cè)服務(wù):
我公司也為客戶(hù)提供單項(xiàng)免疫學(xué)和檢測(cè)服務(wù),如動(dòng)物免疫、動(dòng)物飼養(yǎng)、抗體修飾服務(wù)(如FITC,HRP等的標(biāo)記)、以及ELISA,WB,IHC,DB等檢測(cè)服務(wù)。
抗體定制服務(wù):
已注冊(cè)商標(biāo),主要用于抗體藥物發(fā)現(xiàn)和開(kāi)發(fā),是我公司針對(duì)有特定應(yīng)用要求和各種模型測(cè)試的客戶(hù)量身定制的專(zhuān)業(yè)服務(wù),主要面向工業(yè)客戶(hù)。
產(chǎn)品咨詢(xún)
歡迎您關(guān)注我們的微信了解更多信息
電話(huà)
微信掃一掃